• Norovirus Hijacks NINJ1 for Selective NS1 Secretion: Mechani

  2026-04-24

  This study uncovers how murine norovirus (MNoV) exploits host NINJ1 protein to selectively secrete its viral NS1 protein via an unconventional pathway. The findings provide a mechanistic framework for understanding regulated plasma membrane rupture and selective protein secretion during viral infection, with implications for cell death and immune evasion research.

• Sulfo-NHS-SS-Biotin: Advanced Proteostasis Mapping in Membra

  2026-04-24

  Explore how Sulfo-NHS-SS-Biotin enables precise, reversible biotinylation for advanced studies of membrane protein proteostasis. This article uniquely connects the reagent’s cleavage chemistry with emerging insights into protein folding, trafficking, and quality control, highlighting its utility in next-generation assay design.

• Cy3 NHS Ester (Non-Sulfonated): Technical Use and Workflow G

  2026-04-23

  Cy3 NHS ester (non-sulfonated) enables robust fluorescent labeling of proteins, peptides, and oligonucleotides via amino group conjugation, delivering high sensitivity for biomedical imaging. It is ideal when high solubility in DMSO or ethanol is required but should be avoided for delicate proteins or applications incompatible with organic co-solvents. The product is not suited for protocols demanding water-only solubility or long-term solution storage.

• Silybin A in Liver Disease Research: Applied Protocols & CRI

  2026-04-23

  Silybin A, a principal component of silymarin, is redefining hepatoprotective and metabolic studies through its antioxidant and signaling-modulating actions. This article delivers a bench-to-publication guide, linking Silybin A’s unique properties and solubility constraints to modern workflows, including synergy with CRISPRi-based metabolic interventions.

• HDAC Inhibition Reverses EBV-Induced Dedifferentiation in NP

  2026-04-22

  This study elucidates how EBV latent protein LMP1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma (NPC) by repressing CEBPA via HDAC-mediated chromatin remodeling. The authors demonstrate that HDAC inhibition restores differentiation, offering a mechanistic basis for epigenetic differentiation therapy in solid tumors.

• WY-14643 (Pirinixic Acid): PPARα Agonism in Liver Regenerati

  2026-04-22

  This article provides translational researchers with a mechanistic and strategic roadmap for leveraging WY-14643 (Pirinixic Acid) as a selective PPARα agonist in metabolic, inflammatory, and regenerative liver research. Drawing on recent evidence—including YAP-TEAD signaling's pivotal role in PPARα-induced hepatomegaly—it integrates actionable protocol parameters, competitive context, and future outlook, while referencing both APExBIO's offering and advanced literature assets.

• HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulatio

  2026-04-21

  This study uncovers a novel mechanism in which HOXC8, a homeobox transcription factor, suppresses caspase-1 expression and thereby prevents pyroptotic cell death in non-small cell lung carcinoma (NSCLC). The findings highlight a critical epigenetic axis involving HOXC8 and HDAC1/2 in modulating the caspase signaling pathway, with potential implications for inflammation research and targeted cancer therapies.

• CH 223191 (SKU A8609): Reliable AhR Antagonist for Lab Assay

  2026-04-21

  Discover how CH 223191 (SKU A8609) empowers robust, reproducible assays in cell viability, stem cell differentiation, and dioxin toxicity research. This article addresses real-world laboratory challenges and demonstrates, with scenario-driven evidence, why CH 223191 is a preferred aryl hydrocarbon receptor antagonist for sensitive and reliable workflows.

• EAGLE-2/3: Gepotidacin Versus Nitrofurantoin in UTI—Phase 3

  2026-04-20

  The EAGLE-2 and EAGLE-3 phase 3 trials evaluated the efficacy and safety of gepotidacin, a novel antibiotic, compared to nitrofurantoin for uncomplicated urinary tract infections in females. Gepotidacin demonstrated non-inferiority, and in one study, superiority, with an acceptable safety profile, underscoring its potential as an alternative in the face of rising antibiotic resistance.

• Deferasirox: Oral Iron Chelator for Advanced Cellular Assays

  2026-04-20

  Deferasirox stands apart as an oral iron chelator optimized for both iron overload and cancer research. Its unique mechanistic profile enables robust modulation of iron metabolism, apoptosis, and redox signaling in cellular assays—delivering reproducibility and translational power for challenging workflows.

• Pexidartinib (PLX3397): Technical Workflow for CSF1R Inhibit

  2026-04-19

  Pexidartinib (PLX3397) enables reproducible CSF1R-mediated signaling inhibition in preclinical cancer research and studies focused on the tumor microenvironment. It is best applied for selective macrophage modulation and anti-tumor apoptosis induction, but is not intended for diagnostic or clinical applications. Researchers should follow precise dissolution and storage guidelines to maintain compound integrity.

• Distinct Cell Death Pathways in ALL Induced by Microtubule D

  2026-04-18

  This study reveals that primary acute lymphoblastic leukemia (ALL) cells undergo cell death via different mechanisms when exposed to microtubule depolymerizing agents in G1 versus M phase. These findings advance understanding of microtubule-targeting chemotherapeutic actions and inform potential refinements in cancer treatment strategies.

• Lamotrigine for Epilepsy & Cardiac Sodium Channel Research

  2026-04-17

  Lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine) from APExBIO empowers translational research in epilepsy and cardiac arrhythmia by enabling robust sodium channel and serotonin (5-HT) signaling modulation. This guide delivers actionable workflow enhancements, troubleshooting insights, and protocol parameters validated by recent literature.

• Trifluoperazine 2HCl (SKU B1397): Reliable Assays in Neuroph

  2026-04-16

  This article addresses key laboratory scenarios encountered by researchers and technicians when working with cell viability, proliferation, or cytotoxicity assays involving dopamine receptor signaling. Leveraging Trifluoperazine 2HCl (SKU B1397), it provides advanced, evidence-based guidance for protocol optimization, data reliability, and product selection, helping labs achieve reproducible results in both neuropharmacology and immunology research.

• GPC3-HSP70 mRNA Nanovaccine and PD-L1 Blockade in HCC Immuno

  2026-04-15

  This study introduces an mRNA nanovaccine encoding GPC3 CTL epitopes fused with HSP70, enabling targeted and robust T-cell responses against hepatocellular carcinoma (HCC). The work demonstrates synergistic antitumor efficacy when combined with anti-PD-L1 therapy, setting a new benchmark for mRNA vaccine development in challenging solid tumors.

15837 records 1/1056 page Next 12345 下5页 Last page